Navigation Links
FDA to bring about changes in Marketed Non-Steroidal Anti-Inflammatory Drugs

American drug market watchdog Food and Drug Administration had announced a series of changes to be followed for// the drugs in the class of non-steroidal anti-inflammatory drugs that are sold with or without prescription over the counter. These changes include the withdrawal of the drug Bextra (valdecoxib) from Pfizer, Inc.

Pfizer, Inc was asked to withdraw the drug Bextra as FDA had reports that the overall risk associated with the drug overshadows the benefits. FDA had also asked the drug company to change the label of the drug Celebrex (celecoxib) to include in a box some specific warnings about risk of cardiovascular problems and gastrointestinal bleeding because of the usage of the drug.

Manufacturer of other prescription and nonprescription non-steroidal anti-inflammatory drugs (NSAID) were also asked to provide a similar label highlighting the cardiovascular and gastrointestinal risks associated with the use of the said drugs. The makers of over the counter NSAIDs were also asked to provide information about skin reactions and any other information that will help the consumer to use the drug safely.

In addition to the instructions to the drug manufacturers, FDA had also updated the patient and healthcare practitioner fact sheets.

Reference: www.fda.gov/cder , non-steroidal anti-inflammatory drugs, NSAID, Celebrex, celecoxib, gastrointestinal risks, cardiovascular risks, FDA
'"/>




Page: 1

Related medicine news :

1. Lure of the home turf brings back NRI doctors
2. Acupuncture to bring relief to patients with dry mouth
3. Fame brings wealth but not health
4. Study shows that interventions from health workers can bring about changes in asthma causes
5. Education in women brings sounder sleep
6. Cancer drug brings relief to patients of Crohn’s Diseas
7. India’s smallest premature baby brings immense joy to Indian parent
8. Cyclone Glenda brings Threat of Fatal Mosquito–borne Diseas
9. E-gym is the latest fad: bring the gym home online!
10. Magic mushrooms known to bring relief to patients
11. Anti-smoking efforts bring down cancer death rates
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... Valencia, Calif. (PRWEB) , ... July 19, 2017 , ... ... has acquired the Minnesota based Health IT business unit of Constellation Inc., a move ... an already established base of operations in St. Louis, the acquisition is expected to ...
(Date:7/20/2017)... California (PRWEB) , ... July 19, 2017 , ... A ... that most successful weight loss surgery patients who had received a body contouring procedure ... health and beauty clinic Beverly Hills Physicians (BHP), which provides both types of procedures, ...
(Date:7/20/2017)... ... ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s stories. “Lucky the ... Bieniek Jr. was born in Toledo, Ohio. He attended Woodward High School. He ... married to a brilliant woman with a caring heart named Tiina, who is a hospice ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov and the ... You Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 p.m. ... “Final Rule for Clinical Trials Registration and Results Information,” is a head-scratcher. After ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, ... "Due to menopause, I have frequent hot flashes, and I suffer from anxiety and ... way to keep cool while out and about." INSTA-FAN meets that need. , This ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Corp., also known as ,The Epigenetics Company, announced today the release of ... using the myDNAge ™ test. Based on Horvath,s Clock, so named ... biostatistics at the David Geffen School of Medicine at UCLA ... ™ technology is used to analyze DNA methylation patterns of over ... Epigenetic ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... TRIANGLE PARK, N.C. , July 10, 2017 /PRNewswire/ ... a $5m Convertible Note to support the development of ... by Tencent Holdings Limited, a leading Chinese Internet services ... This funding will advance multiple infectious disease product programs ... Founded by Dr. ...
Breaking Medicine Technology: